PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Marinomed Biotech AG

27.01.2020 – 14:00

Marinomed Biotech AG

EANS-Voting Rights: Marinomed Biotech AG
Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act

--------------------------------------------------------------------------------
  Notification of voting rights transmitted by euro adhoc with the aim of a
  Europe-wide distribution. The issuer is responsible for the content of this
  announcement.
--------------------------------------------------------------------------------


Overview
1. Issuer: Marinomed Biotech AG
2. Reason for the notification: Acquisition or disposal of voting rights
3. Person subject to notification obligation
Acting in concert (Sec. 133 No. 7 BörseG 2018)
 ____________________________________________________________________________
|   First name    |    Name/Surname     |        City         |   Country    |
|_________________|_____________________|_____________________|______________|
|Abdulmohsen      |Al Sheikh            |                     |              |
|_________________|_____________________|_____________________|______________|
|Mohammed         |Al Sheikh            |                     |              |
|_________________|_____________________|_____________________|______________|
|                 |Acropora Beteiligungs|                     |              |
|                 |GmbH                 |Vienna               |Austria       |
|_________________|_____________________|_____________________|______________|

4. Name of shareholder(s):
5. Date on which the threshold was crossed or reached: 22.1.2020
6. Total positions:
 ______________________________________________________________________________
|               |               |  % of voting  |             |                |
|               |               |rights through |             |                |
|               |  % of voting  |financial/other|Total of both|Total number of |
|               |rights attached| instruments   |in % (7.A +  |voting rights of|
|               |to shares (7.A)|(7.B.1 + 7.B.2)|7.B)         |     issuer     |
|_______________|_______________|_______________|_____________|________________|
|Resulting      |               |               |             |                |
|situation on   |               |               |             |                |
|the date on    |               |               |             |                |
|which threshold|    16.59 %    |    0,00 %     |   16.59 %   |1,469,772       |
|was crossed /  |               |               |             |                |
|reached        |               |               |             |                |
|_______________|_______________|_______________|_____________|________________|
|Position of    |               |               |             |                |
|previous       |               |               |             |                |
|notification   |    23.27 %    |    0,00 %     |   23.27 %   |                |
|(if applicable)|               |               |             |                |
|_______________|_______________|_______________|_____________|________________|


Details
7. Notified details of the resulting situation:
 ______________________________________________________________________________
|A: Voting rights attached to shares                                           |
|______________________________________________________________________________|
|            |Number of voting rights        |% of voting rights               |
|            |_______________________________|_________________________________|
|            |    Direct     |Indirect (Sec  |     Direct     |Indirect (Sec   |
|ISIN Code   |(Sec 130 BörseG|133 BörseG     |(Sec 130 BörseG |133 BörseG      |
|            |     2018)     |2018)          |     2018)      |2018)           |
|____________|_______________|_______________|________________|________________|
|AT0000831706|        243,860|               |         16.59 %|                |
|____________|_______________|_______________|________________|________________|
|SUBTOTAL A  |                        243,860|                           16.59%|
|____________|_______________________________|_________________________________|


 __________________________________________________________________________
|B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1     |
|BörseG 2018                                                               |
|__________________________________________________________________________|
|          |               |                 |Number of voting |           |
|          |               |                 | rights that may |           |
|Type of   |               |                 | be acquired if  |% of voting|
|instrument|Expiration Date|  Exercise Period|the instrument is|rights     |
|          |               |                 |    exercised    |           |
|__________|_______________|_________________|_________________|___________|
|__________|_______________|_________________|_________________|___________|
|                          |     SUBTOTAL B.1|                 |           |
|__________________________|_________________|_________________|___________|


 ________________________________________________________________________
|B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2   |
|BörseG 2018                                                             |
|________________________________________________________________________|
|          |Expiration|Exercise|Physical / Cash|Number of    |% of voting|
|Type of   |Date      |Period  |Settlement     |voting rights|rights     |
|instrument|__________|________|_______________|_____________|___________|
|__________|__________|________|_______________|_____________|___________|
|                              | SUBTOTAL B.2  |             |           |
|______________________________|_______________|_____________|___________|


8. Information in relation to the person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the
financial/other instruments are effectively held starting with the ultimate
controlling natural person or legal entity:
 _____________________________________________________________________________
|          |            |           |             |Financial/   |             |
|          |            | Directly  |             |other        |             |
|          |            |controlled | Shares held |instruments  |Total of both|
|   No.    |    Name    |  by No.   |directly (%) |held directly|     (%)     |
|          |            |           |             |     (%)     |             |
|__________|____________|___________|_____________|_____________|_____________|
|          |Abdulmohsen |           |             |             |             |
|    1     |Al Sheikh   |           |             |             |             |
|__________|____________|___________|_____________|_____________|_____________|
|          |Mohammed Al |           |             |             |             |
|    2     |Sheikh      |           |             |             |             |
|__________|____________|___________|_____________|_____________|_____________|
|          |Acropora    |           |             |             |             |
|    3     |Beteiligungs|    1,2    |      16.59 %|             |      16.59 %|
|          |GmbH        |           |             |             |             |
|__________|____________|___________|_____________|_____________|_____________|


9. In case of proxy voting
Date of general meeting: -
Voting rights after general meeting: - is equivalent to - voting rights.

10. Additional comments:
The disclosure obligation arose because the number of shares held dropped below
the threshold due to the sale of 73,500 shares.



Further inquiry note:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement                         euro adhoc
--------------------------------------------------------------------------------


 
issuer:       Marinomed Biotech AG
              Veterinärplatz 1
              A-1210 Wien
phone:        0043250774460
FAX:          0043250774493
mail:      office@marinomed.com
WWW:       www.marinomed.com
ISIN:         ATMARINOMED6, AT0000A1WD52
indexes:      
stockmarkets: Wien
language:     English
 

Original content of: Marinomed Biotech AG, transmitted by news aktuell